Keros Therapeutics (KROS) Current Deferred Revenue (2025)

Keros Therapeutics' (KROS) quarterly Current Deferred Revenue came in at $155000.0 in Q3 2025, down 83.24% on a QoQ basis from $925000.0 in Q2 2025.

Keros Therapeutics (KROS) Current Deferred Revenue (2025) Analysis & Trends

Keros Therapeutics (KROS) has 1 years of Current Deferred Revenue data on file, last reported at $155000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Keros Therapeutics	217.61 Mn	-40.00 Mn	-

Download Data